Skip to main content
Top
Published in: Current Pain and Headache Reports 5/2012

01-10-2012 | Myofascial Pain (RD Gerwin, Section editor)

Botulinum Toxin Treatment of Myofascial Pain: A Critical Review of the Literature

Author: Robert Gerwin

Published in: Current Pain and Headache Reports | Issue 5/2012

Login to get access

Abstract

This is a review of literature relevant to the treatment of myofascial pain syndrome by botulinum injections. The objective is to critically review the studies to see if they are appropriately designed, conducted, and interpreted to provide guidance in the management of myofascial pain. The intent is to better understand the mixed results that these studies have provided. A search was made utilizing PubMed for literature relevant to the use of botulinum toxin in the treatment of myofascial pain. All identifiable series were reviewed, including open label, single-blinded and double-blinded studies, randomized and controlled, or not. In general, small case series of only a few patients were not included unless they made a relevant point and there were no available randomized studies or larger studies. Single case reports were not included. This is not a meta-analysis. The studies were evaluated according to their design and the selection of outcome measurements, and the interpretation of results. The studies were individually critiqued, and an overall assessment and commentary was made of the studies in the field as a whole. Problems that were common to the studies were robust placebo responders, incomplete treatment of a regional myofascial pain syndrome, inappropriate or confounding control populations or treatments, and inappropriate time periods for assessment of outcomes, or misinterpretation of the time-frame of action of botulinum toxin. The studies of the effect of botulinum toxin treatment of myofascial trigger points have had mixed results. However, few studies have been designed to avoid many of the pitfalls associated with a trial of botulinum toxin treatment of trigger points. Better-designed studies may give results that can be used to guide practice based on reliable evidence. At the present time, one must conclude that the available evidence is insufficient to guide clinical practice.
Literature
1.
go back to reference •• Ballyns JJ, Shah JP, Hammond J, Bebreab T, Gerber LH, Sikdar S. Objective sonographic measures for characterizing myofascial trigger points associated with cervical pain. J Ultrasound Med. 2011;30:1331–40. This is one of two techniques that identify the trigger point taut band by imaging techniques, providing objective confirmation of the physical examination. In this technique the taut band of the trigger point appears as a hypoechoic region distinct from its surroundings. PubMed •• Ballyns JJ, Shah JP, Hammond J, Bebreab T, Gerber LH, Sikdar S. Objective sonographic measures for characterizing myofascial trigger points associated with cervical pain. J Ultrasound Med. 2011;30:1331–40. This is one of two techniques that identify the trigger point taut band by imaging techniques, providing objective confirmation of the physical examination. In this technique the taut band of the trigger point appears as a hypoechoic region distinct from its surroundings. PubMed
2.
go back to reference Chen Q, Bensamoun S, Basford J, Thompson JM, An K-N. Identification and quantification of myofascial taut bands with magnetic resonance elastography. Arch Phys Med Rehabil. 2007;88:1658–61.PubMedCrossRef Chen Q, Bensamoun S, Basford J, Thompson JM, An K-N. Identification and quantification of myofascial taut bands with magnetic resonance elastography. Arch Phys Med Rehabil. 2007;88:1658–61.PubMedCrossRef
3.
go back to reference Shah JP, Phillips TM, Danoff JV, Gerber LH. An in vivo microanalytic technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol. 2005;99:1977–84.PubMedCrossRef Shah JP, Phillips TM, Danoff JV, Gerber LH. An in vivo microanalytic technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol. 2005;99:1977–84.PubMedCrossRef
4.
go back to reference Kuan TS, Chen JT, Chen SM, Chien SH, Hong CZ. Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil. 2002;81:512–20.PubMedCrossRef Kuan TS, Chen JT, Chen SM, Chien SH, Hong CZ. Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil. 2002;81:512–20.PubMedCrossRef
5.
go back to reference Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43 Suppl 1:S9–15.PubMedCrossRef Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43 Suppl 1:S9–15.PubMedCrossRef
6.
go back to reference • Sim WS. Application of botulinum toxin in pain management. Korean J Pain. 2011;24:1–6. This study demonstrates the important point that the release of neurotransmitters and excitatory amino acids from sensory nerve endings is inhibited by botulinum toxin, and can therefore inhibit nociceptive nerve activation. PubMedCrossRef • Sim WS. Application of botulinum toxin in pain management. Korean J Pain. 2011;24:1–6. This study demonstrates the important point that the release of neurotransmitters and excitatory amino acids from sensory nerve endings is inhibited by botulinum toxin, and can therefore inhibit nociceptive nerve activation. PubMedCrossRef
7.
go back to reference Lew MF, Chinnapongse R, Zhang Y, Corliss M. Rimabotulinum B effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosurg. 2010;120:2989–300. Lew MF, Chinnapongse R, Zhang Y, Corliss M. Rimabotulinum B effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosurg. 2010;120:2989–300.
8.
go back to reference Jancovic J, Orman J. Botulinum toxin for cranial cervical dystonia: a double-blind, placebo controlled study. Neurol. 1987;37:616–23.CrossRef Jancovic J, Orman J. Botulinum toxin for cranial cervical dystonia: a double-blind, placebo controlled study. Neurol. 1987;37:616–23.CrossRef
9.
go back to reference Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain. 2003;4:159–66.PubMedCrossRef Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain. 2003;4:159–66.PubMedCrossRef
10.
go back to reference Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal horn ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245–58.PubMedCrossRef Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal horn ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245–58.PubMedCrossRef
11.
go back to reference Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion form trigeminal nerve cells by botulinum toxin type A. Implications for migraine therapy. Headache. 2004;44:35–43.PubMedCrossRef Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion form trigeminal nerve cells by botulinum toxin type A. Implications for migraine therapy. Headache. 2004;44:35–43.PubMedCrossRef
12.
go back to reference Cui M, Khanijou S, Rubino J. Aoki KR Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–33. human model of trigeminal sensitization. Pain. 2006;122:15–25.PubMedCrossRef Cui M, Khanijou S, Rubino J. Aoki KR Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–33. human model of trigeminal sensitization. Pain. 2006;122:15–25.PubMedCrossRef
13.
go back to reference • Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141:60–9. This is an important study that shows that botulinum toxin has an action at sensory nerve receptors, not just at the neuromuscular junction. PubMedCrossRef • Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141:60–9. This is an important study that shows that botulinum toxin has an action at sensory nerve receptors, not just at the neuromuscular junction. PubMedCrossRef
14.
go back to reference Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilitation in human skin. Pain. 2007;130:76–83.PubMedCrossRef Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilitation in human skin. Pain. 2007;130:76–83.PubMedCrossRef
15.
go back to reference Voller B, Sucha T, Gustorff B, Schmetterer L, Lehr S, Eichler HG, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurol. 2003;61:940–4.CrossRef Voller B, Sucha T, Gustorff B, Schmetterer L, Lehr S, Eichler HG, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurol. 2003;61:940–4.CrossRef
16.
go back to reference Ferrante FM, Bean L, Rothrock R, King L. Evidence against trigger point injection techniques for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiol. 2005;103:377–83.CrossRef Ferrante FM, Bean L, Rothrock R, King L. Evidence against trigger point injection techniques for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiol. 2005;103:377–83.CrossRef
17.
go back to reference Graboski CL, Gray DS, Burnham RS. Botulinum toxin A vs bupivicaine trigger point injections for the treatment of myofascial pain syndrome: a randomized double blind crossover study. Pain. 2005;118:170–5.PubMedCrossRef Graboski CL, Gray DS, Burnham RS. Botulinum toxin A vs bupivicaine trigger point injections for the treatment of myofascial pain syndrome: a randomized double blind crossover study. Pain. 2005;118:170–5.PubMedCrossRef
18.
go back to reference Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumat Int. 2005;25:604–11.CrossRef Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumat Int. 2005;25:604–11.CrossRef
19.
go back to reference •• Lucas KR. The impact of latent trigger points on regional muscle function. Curr Pain Headache Rep. 2008;12:344–9. This is the first study to establish the importance of latent trigger points in the orderly recruitment of muscles in a volitional activity. As such, it demonstrated the ability of latent trigger points to produce a dysfunction, showing that latent trigger points were not inert. PubMedCrossRef •• Lucas KR. The impact of latent trigger points on regional muscle function. Curr Pain Headache Rep. 2008;12:344–9. This is the first study to establish the importance of latent trigger points in the orderly recruitment of muscles in a volitional activity. As such, it demonstrated the ability of latent trigger points to produce a dysfunction, showing that latent trigger points were not inert. PubMedCrossRef
20.
go back to reference Ojala T, Arokoski JPA, Partanen J. The effect of small doses of botulinum toxin A on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain. 2006;22:90–6.PubMedCrossRef Ojala T, Arokoski JPA, Partanen J. The effect of small doses of botulinum toxin A on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain. 2006;22:90–6.PubMedCrossRef
21.
go back to reference Benecke R, Heinze A, Reichel G, Hefter H, Göbel H. Dysport myofascial pain study group. Botulinum type A toxin complex for the relief of upper back myfascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections. Pain Med. 2011;12:1607–14.PubMedCrossRef Benecke R, Heinze A, Reichel G, Hefter H, Göbel H. Dysport myofascial pain study group. Botulinum type A toxin complex for the relief of upper back myfascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections. Pain Med. 2011;12:1607–14.PubMedCrossRef
22.
go back to reference Gül I, Onal SA. Comparison of non-invasive and invasive techniques in the treatment of patients with myofascial pain syndrome. Aqri. 2009;21:104–12. Turkish. Gül I, Onal SA. Comparison of non-invasive and invasive techniques in the treatment of patients with myofascial pain syndrome. Aqri. 2009;21:104–12. Turkish.
23.
go back to reference De Andrés J, Adsuara VM, Palmisani S, Villanueva V, López-Alarcón. A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans. Reg Anesth Pain Med. 2010;35:255–60.PubMedCrossRef De Andrés J, Adsuara VM, Palmisani S, Villanueva V, López-Alarcón. A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans. Reg Anesth Pain Med. 2010;35:255–60.PubMedCrossRef
24.
go back to reference Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain. Neurol. 2001;56:1290–3.CrossRef Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain. Neurol. 2001;56:1290–3.CrossRef
25.
go back to reference Jabbari B, Ney J, Sichani A, Monacci W, Foster L, Difazio M. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study. Pain Med. 2006;7:260–4.PubMedCrossRef Jabbari B, Ney J, Sichani A, Monacci W, Foster L, Difazio M. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study. Pain Med. 2006;7:260–4.PubMedCrossRef
26.
go back to reference Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicenter study. Pain. 2006;125:82–8.PubMedCrossRef Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicenter study. Pain. 2006;125:82–8.PubMedCrossRef
27.
go back to reference Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine. 1998;23:1662–66.PubMedCrossRef Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine. 1998;23:1662–66.PubMedCrossRef
28.
go back to reference Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B. Botulinum neurotoxin-A for treatment of refractory neck pain: a randomized, double-blind study. Pain Med. 2009;10:1012–17.PubMedCrossRef Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B. Botulinum neurotoxin-A for treatment of refractory neck pain: a randomized, double-blind study. Pain Med. 2009;10:1012–17.PubMedCrossRef
29.
go back to reference Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008;66:1644–51.PubMedCrossRef Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008;66:1644–51.PubMedCrossRef
30.
go back to reference Emberg M, Hedenberg-Mangusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain. 2011;152:1988–96.CrossRef Emberg M, Hedenberg-Mangusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain. 2011;152:1988–96.CrossRef
31.
go back to reference von Lindern J, Niederhagan B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61:774–8.CrossRef von Lindern J, Niederhagan B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61:774–8.CrossRef
32.
go back to reference • Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2012;4:CD007533. Cochrane reviews are always held in high regard. This review found only 4 studies that met its criteria, and bases its conclusions on a narrow sample. However, the conclusion that there is not enough data to make an informed decision in favor of the effects of botulinum in the treatment of myofascial trigger points is valid. PubMed • Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2012;4:CD007533. Cochrane reviews are always held in high regard. This review found only 4 studies that met its criteria, and bases its conclusions on a narrow sample. However, the conclusion that there is not enough data to make an informed decision in favor of the effects of botulinum in the treatment of myofascial trigger points is valid. PubMed
33.
go back to reference Simons DG, Travell JG, Simons LS. Myofascial Pain and Dysfunction: the trigger point manual. Baltimore: Williams & Wilkins; 1999. p. 31–5. Simons DG, Travell JG, Simons LS. Myofascial Pain and Dysfunction: the trigger point manual. Baltimore: Williams & Wilkins; 1999. p. 31–5.
34.
go back to reference Zhang T, Adatia A, Zarin W, Moitri W, Vijenthira A, Chu R, et al. The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain”: a systematic review and meta analysis. Inflammopharmacol. 2011;19:21–34.CrossRef Zhang T, Adatia A, Zarin W, Moitri W, Vijenthira A, Chu R, et al. The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain”: a systematic review and meta analysis. Inflammopharmacol. 2011;19:21–34.CrossRef
35.
go back to reference Jabbari B, Machado D. Treatment of refractory pain with botulinum toxins– an evidence-based review. Pain Med. 2011;12:1594–606.PubMedCrossRef Jabbari B, Machado D. Treatment of refractory pain with botulinum toxins– an evidence-based review. Pain Med. 2011;12:1594–606.PubMedCrossRef
36.
go back to reference Harden RN, Cottrill J, Gagnon CM, Smitherman TA, Weinland SR, Tann B, et al. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache. 2009;49:732–43.PubMedCrossRef Harden RN, Cottrill J, Gagnon CM, Smitherman TA, Weinland SR, Tann B, et al. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache. 2009;49:732–43.PubMedCrossRef
37.
go back to reference Venancio RA, Alencar Jr FG, Zamperini C. Botulinum toxin, lidocaine, and dry needling injections in patients with myofascial pain and headaches. Cranio. 2009;27:46–53. Venancio RA, Alencar Jr FG, Zamperini C. Botulinum toxin, lidocaine, and dry needling injections in patients with myofascial pain and headaches. Cranio. 2009;27:46–53.
38.
go back to reference Langevin P, Peloso PM, Lowcock J, Nolan M, Weber J, Gross A, et al. Botulinum toxin for subacute/chronic neck pain. Cochrane Database Syst Review. 2011;6:CD008626. Langevin P, Peloso PM, Lowcock J, Nolan M, Weber J, Gross A, et al. Botulinum toxin for subacute/chronic neck pain. Cochrane Database Syst Review. 2011;6:CD008626.
39.
go back to reference Braker C, Yariv S, Adler R, Badarny S, Eisenberg E. The analgesic effect of botulinum-toxin A on postwhiplash neck pain. Clin J Pain. 2008;24:5–10.PubMedCrossRef Braker C, Yariv S, Adler R, Badarny S, Eisenberg E. The analgesic effect of botulinum-toxin A on postwhiplash neck pain. Clin J Pain. 2008;24:5–10.PubMedCrossRef
40.
go back to reference Carroll A, Barnes M, Comiskey C. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder. Clin Rehabil. 2008;22:513–19.PubMedCrossRef Carroll A, Barnes M, Comiskey C. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder. Clin Rehabil. 2008;22:513–19.PubMedCrossRef
41.
go back to reference Safarpour D, Jabbari B. Botulinum toxin A (Botox) for treatment of proximal myofascial pain in complex regional pain syndrome: two cases. Pain Med. 2010;11:1415–18.PubMedCrossRef Safarpour D, Jabbari B. Botulinum toxin A (Botox) for treatment of proximal myofascial pain in complex regional pain syndrome: two cases. Pain Med. 2010;11:1415–18.PubMedCrossRef
42.
go back to reference Taylor M, Silva S, Cottrell C. Botulinum toxin type-A (Botox) in the treatment of occipital neuralgia: a pilot study. Headache. 2008;48:1476–81.PubMedCrossRef Taylor M, Silva S, Cottrell C. Botulinum toxin type-A (Botox) in the treatment of occipital neuralgia: a pilot study. Headache. 2008;48:1476–81.PubMedCrossRef
43.
go back to reference Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurol. 2006;67:241–5.CrossRef Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurol. 2006;67:241–5.CrossRef
Metadata
Title
Botulinum Toxin Treatment of Myofascial Pain: A Critical Review of the Literature
Author
Robert Gerwin
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Pain and Headache Reports / Issue 5/2012
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-012-0287-6

Other articles of this Issue 5/2012

Current Pain and Headache Reports 5/2012 Go to the issue

Perimenstrual Headache (S Evers, Section Editor)

Hormonal Contraception and Migraine: Clinical Considerations

Perimenstrual Headache (S Evers, Section Editor)

Perimenstrual Headache in Adolescence

Myofascial Pain (RD Gerwin, Section editor)

Myofascial Pelvic Pain